Video

Dr. Phillips on the Safety of Acalabrutinib Plus Bendamustine/Rituximab in MCL

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses the safety of acalabrutinib (Calquence) plus bendamustine and rituximab (BR; Rituxan) in patients with mantle cell lymphoma (MCL).

At the 2018 ASH Annual Meeting, Phillips presented data on the combination of acalabrutinib and BR in patients with treatment-naïve or relapsed/refractory MCL. High efficacy rates were observed, especially in treatment-naïve patients. Moreover, over 70% of patients experienced a complete response rate.

The combination was deemed safe and effective. Adverse-events seemed to be evenly dispersed between the treatment-naïve and relapsed/refractory patients. Traditionally, bendamustine is a safe backbone upon which to test novel therapies, says Phillips. Although a high rate of infection has been noted in other studies with bendamustine, this was not the case with the addition of acalabrutinib, he explains. Further analysis into T cell subsets could provide additional insight into the potential risk for infection.

Related Videos
Consuelo Bertossi, MD
Michael R. Grunwald, MD, FACP
Sundar Jagannath, MBBS
Kevin Kalinsky, MD, MS,
Aaron Gerds, MD
Paolo Tarantino, MD
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Shella Saint Fleur-Lominy, MD, PhD
Benjamin Levy, MD
Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute